AOAndrew OwenBSS, MSC, PhD, FSBVideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Pharmacogenetics - Back to reality | Andrew Owen, BSS, MSC, PhD, FSBView Video
KSKimberly ScarsiPharmD, MS, FCCPVideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Looking Backwards: Hormonal Contraception and ART | Kimberly Scarsi, PharmD, MS, FCCPView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Janssen - Rilpivirine | Herta Crauwels, PhDView Video
ADKAngela D.M. KashubaBScPhm, PharmD, DABCP, FCPVideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Target Concentrations | Angela Kashuba, PharmDView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016The FDA Perspective on Hepatitis C Drug Resistance | Patrick Harrington, PHDView Video
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika | Steven Kern, PhDView Video
AOAndrew OwenBSS, MSC, PhD, FSBVideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Long acting (LA) drug delivery in TB treatment | Andrew Owen, BSS, MSC, PhD, FSBView Video
VideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Lost in translation: learning from preclinical data | Gerry DaviesView Video
CPCharles PeloquinPharmDVideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmDView Video
VideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Kelly Dooley, MD, PhDView Video
VideoTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016A new model for early clinical development of TB drugs and its application to Q203 and BTZ043 | Norbert Heinrich, MDView Video
SlidesetTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016Pharmacokinetic Modeling and Simulation of the Interaction between Moxifloxacin and Rifapentine in Healthy Volunteers | M. ImperialView Slideset
